Life Science IPOs Catch a Second Wind

Kailera Therapeutics’ blockbuster debut and strong aftermarket performance are emboldening biotech issuers — many backed by hedge funds — to test markets again.

Stephen Taub April 22, 2026

The IPO calendar is picking up again in biopharma, buoyed by a pair of recent offerings that delivered strong returns. Kailera Therapeutics’ record-setting debut last week, followed closely by Alamar Biosciences’ strong aftermarket performance, is lifting sentiment for drugmakers waiting to price their own deals

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2026 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

4.19.03 build:2026-04-21 Login